Each year, lung cancer quietly claims nearly 9,000 Australian lives — not always because treatment arrives too late, but because diagnosis itself takes too long. Researchers at the University of Queensland have designed a nanodevice that reads molecular sugar codes on particles floating in a single drop of blood, distinguishing cancerous tissue from healthy cells before the disease has time to entrench itself. In doing so, they have not merely improved a test — they have challenged the assumption that early detection must be slow, expensive, and invasive.
Australian researchers develop blood test to detect early-stage lung cancer
Lung cancer claims approximately 9,000 lives annually in Australia, making early detection critical for improving patient survival outcomes.
A drop of blood could catch the disease before it spreads
Mark
Why does the current process for detecting lung cancer take so long?
Mimi
Because we're looking for something we can't see without imaging. A suspicious shadow on a CT scan doesn't tell you if it's cancer or just scar tissue. So you do more scans, then a biopsy, then wait for pathology. Each step takes time and money.
Mark
And this blood test skips all that?
Mimi
Not entirely—you'd still need imaging to find the nodule in the first place. But once you have a suspicious finding, instead of weeks of additional testing, you could have a definitive answer from blood in days.
Mark
How does looking at sugar molecules tell you if something is cancer?
Mimi
Cancer cells have a different metabolic signature. The way they coat their messenger particles—the glycans—is distinct from healthy cells. It's like a fingerprint that only malignant cells leave.
Mark
The trial was only 40 people. Is that enough to trust it?
Mimi
It's enough to show the concept works. It's not enough to put it in every clinic tomorrow. But it's the right size for a proof-of-concept study—you validate the principle before scaling up.
Mark
What happens if this works at scale? What changes?
Mimi
The entire timeline compresses. Right now, a patient waits weeks in uncertainty. With this, they get answers faster, and if it is cancer, they start treatment while it's still early. That's when survival rates are best.
Mark
Could this work for other cancers?
Mimi
That's the real possibility. If the glycan signature is reliable for lung cancer, the same approach might work for ovarian cancer, pancreatic cancer, others. You're not inventing a new test for each disease—you're using the same principle across many.
Il Polso
- Lung cancer remains Australia's deadliest cancer in part because the diagnostic journey — scans, imaging, biopsies — consumes precious time while the disease advances.
- A nanodevice developed at the University of Queensland can now read glycan sugar signatures on extracellular vesicles in blood, revealing malignancy from a single drop without needles or imaging equipment.
- A clinical trial of 40 patients successfully separated malignant from benign lung nodules, suggesting the glycan code is reliable enough to guide real clinical decisions.
- The technology could compress weeks of confirmatory testing into days, widening the window for early intervention when survival rates are highest and treatment burden is lowest.
- Researchers believe the same glycan-reading principle may extend to other cancers and diseases, positioning this device as a proof of concept for a broader transformation in early diagnosis.
Each year, lung cancer quietly claims nearly 9,000 Australian lives — not always because treatment arrives too late, but because diagnosis itself takes too long. Researchers at the University of Queensland have designed a nanodevice that reads molecular sugar codes on particles floating in a single drop of blood, distinguishing cancerous tissue from healthy cells before the disease has time to entrench itself. In doing so, they have not merely improved a test — they have challenged the assumption that early detection must be slow, expensive, and invasive.
Lung cancer kills nearly 9,000 Australians every year, yet the path to catching it early remains slow and costly — a succession of scans, biopsies, and waiting rooms that stretch the time between suspicion and certainty. Researchers at the University of Queensland's Australian Institute for Bioengineering and Nanotechnology have built something that could change that: a nanodevice requiring nothing more than a single drop of blood.
Dr Richard Lobb and Quan Zhou designed the device to detect glycans — sugar molecules that coat extracellular vesicles, tiny particles cells release into the bloodstream. The critical discovery is that cancer cells coat these vesicles differently than healthy cells do. By reading that molecular signature, the device can identify early-stage lung cancer non-invasively, with no imaging equipment and no tissue sampling required.
In a clinical trial of 40 patients, the nanodevice successfully distinguished malignant lung nodules from benign ones — a result significant enough to suggest real clinical utility. The research, led by Professor Matt Trau's laboratory and published in Advanced Science, points toward a future where weeks of confirmatory testing could be compressed into days, opening a wider window for intervention while survival odds remain highest.
Quan Zhou noted that the implications reach beyond lung cancer. If glycan signatures can reliably identify malignant nodules in the lung, the same principle may apply to other cancers and conditions, potentially reshaping how clinicians approach screening across medicine. For now the work is validated in a small cohort, but the direction is clear: a simpler, faster, and more humane way of reading what the body already knows.
Lung cancer kills nearly 9,000 Australians every year. It is the country's deadliest cancer. Yet the path to catching it early remains cumbersome—a series of scans, imaging tests, biopsies, each one stretching out the time between suspicion and diagnosis, each one adding cost and delay. Researchers at the University of Queensland have now built a device that could collapse that timeline into something far simpler: a single drop of blood.
Dr Richard Lobb and Quan Zhou, working at the Australian Institute for Bioengineering and Nanotechnology, have designed a nanodevice that hunts for a specific signature in the bloodstream. The device looks for glycans—sugar molecules that coat tiny particles called extracellular vesicles, which float through the blood carrying messages between cells. The key insight is that cancer cells coat these particles differently than healthy cells do. The sugar code is distinct. Read that code correctly, and you can spot malignancy before it has time to spread.
The technology is non-invasive, which matters. It requires no imaging equipment, no needles threading into the lung, no waiting rooms. A clinician draws blood, the device analyzes it, and within a framework that current diagnostic protocols cannot match, the presence of early-stage lung cancer nodules becomes visible. The speed and simplicity of the approach could allow intervention while the disease is still young—before it has metastasized, before treatment options narrow, before the odds shift against the patient.
A clinical trial involving 40 patients tested the device's ability to distinguish between malignant and benign lung nodules. It worked. The nanodevice successfully separated the two groups, suggesting that the glycan signature is reliable enough to guide real clinical decisions. The research, conducted by Professor Matt Trau's laboratory with contributions from AIBN scholars Xueming Niu, Alain Wuethrich, and Zhen Zhang, was published in Advanced Science.
What makes this development significant is not just the technical achievement, though that is real. It is the possibility of shifting the entire diagnostic paradigm. Currently, a patient with a suspicious finding on imaging faces weeks of additional testing to confirm what they might have. With this blood test, that confirmation could come in days. The window for early intervention—when survival rates are highest and treatment burden is lowest—would widen considerably.
Zhou noted that the implications extend beyond lung cancer. If glycan signatures can identify malignant lung nodules, they may also identify other diseases in their early stages. The same principle, applied to different cancers or different conditions altogether, could transform how clinicians approach screening and diagnosis across multiple domains. The device represents not just a solution to one problem, but a proof of concept for a broader approach to catching disease before it becomes entrenched.
For now, the work remains in the research phase, validated in a small clinical cohort. But the path from laboratory to clinic is becoming clearer. A simple blood test, a nanodevice, and a new way of reading the body's own signals—these could soon change what early detection means for thousands of Australians facing a lung cancer diagnosis.
Citazioni salienti
A drop of blood can be all that's needed to alert clinicians to the presence of small lung cancer nodules and allow intervention while the disease is in its early stages— Dr Richard Lobb, University of Queensland
The sugar code on a cancer cell is different to a normal cell, making glycans excellent biomarkers for detection— Dr Richard Lobb
Vuoi la storia completa?
Leggi l'originale su News-Medical.net ↗
Health & Medicine